AEC Routemaster

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

Retrieved on: 
Tuesday, October 31, 2023
Survival, Sale, SynCo Bio Partners, AEC, Xbox Series X and Series S, Molecular biology, EDT, Fibrosis, Idiopathic pulmonary fibrosis, Acquisition, AEC Routemaster, United, IPF, Lung, Bios, Interim, University, ALRN, Therapy, Patient, Diagnosis, Moses Austin, Pharmaceutical industry, Management, Aileron

WALTHAM, Mass. and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. Immediately following the acquisition of Lung Tx, Aileron entered into a definitive agreement for the sale of shares of Aileron's Series X non-voting convertible preferred stock (the "Series X preferred stock") and warrants to purchase shares of Aileron's common stock in a private placement to a group of accredited investors led by Bios Partners ("Bios"), and including Nantahala Capital, as well as additional undisclosed investors. The private placement is expected to result in gross proceeds to Aileron of approximately $18 million before deducting placement agent fees and other offering expenses. Aileron intends to use the proceeds from the private placement primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of IPF, and for general corporate purposes. 

Key Points: 
  • and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments.
  • "We are pleased to announce that after a thorough evaluation of strategic alternatives, we have completed the acquisition of Lung Therapeutics, which we believe represents a value-creation opportunity for Aileron's stockholders.
  • "Lung Therapeutics has built a promising clinical-stage pipeline for life-threatening lung conditions, and we believe in the ability of our combined companies to deliver value to both patients and stockholders."
  • I want to thank the board and entire team of Lung Therapeutics for all their hard work with this transaction."

Credo to Showcase Datacenter AI, Compute and CXL at OCP Global Summit in San Jose

Retrieved on: 
Monday, October 16, 2023
Technology, Venture Capital, Other Technology, Professional Services, Software, Networks, Internet, Hardware, Data Management, Multimedia, CXL, Business, World of McIntosh Experience Center, AI, Expo Hall, DriveNets, Meta, Rack, RDMA, AEC Routemaster, Synthetic media, UCIe, OCP, Credo, Instrumentation, Medical device, SerDes

Credo Technology Group Holding Ltd (“Credo”) (Nasdaq: CRDO), an innovator in providing secure, high-speed connectivity solutions that deliver improved power and energy-efficiency, is excited to announce its participation in the upcoming OCP Global Summit on October 17-19,2023 in San Jose, CA.

Key Points: 
  • Credo Technology Group Holding Ltd (“Credo”) (Nasdaq: CRDO), an innovator in providing secure, high-speed connectivity solutions that deliver improved power and energy-efficiency, is excited to announce its participation in the upcoming OCP Global Summit on October 17-19,2023 in San Jose, CA.
  • OCP provides Credo with a platform to showcase generative AI, general compute and operator focused connectivity solutions.
  • View the full release here: https://www.businesswire.com/news/home/20231016050756/en/
    The OCP Global Summit provides Credo with a platform to showcase our generative AI, general compute and operator focused connectivity solutions.
  • Credo invites all OCP Global Summit attendees to visit booth #B10 and the Rack and Power Experience Center and attend our presentations to learn more.

Optomind and MaxLinear announce collaboration on PAM4 112Gbps OSFP 800Gbps SR8 transceiver solution at ECOC Exhibition 2023

Retrieved on: 
Sunday, October 1, 2023
Data Management, Technology, Manufacturing, Nanotechnology, Networks, Other Manufacturing, Hardware, SR, MXL, Mechanics, OSFP, MaxLinear, GPT, DSP, SR8, Mexicali, OSA, AOC, EML, Tias, HPC, Exhibition, Architecture, Ecosystem, ECOC, AEC Routemaster, VCSEL, Family, AOCS, Telecommunications, Video game

Optomind and MaxLinear will be demonstrating 800Gbps OSFP active optical cables (AOC) and SR8 optical transceivers at ECOC 2023 Exhibition, in Glasgow, Scotland, October 2-4 (Booth #775, Optomind; #776, MaxLinear).

Key Points: 
  • Optomind and MaxLinear will be demonstrating 800Gbps OSFP active optical cables (AOC) and SR8 optical transceivers at ECOC 2023 Exhibition, in Glasgow, Scotland, October 2-4 (Booth #775, Optomind; #776, MaxLinear).
  • Optomind has developed the best-in-class PAM4 100Gbps/lane SR optical transceivers and AOCs using MaxLinear's 5nm Keystone PAM4 DSP.
  • The low-power, high-performance AOCs and transceivers that Optomind and MaxLinear have developed together are ideal for these applications.
  • Optomind selected MaxLinear's 5nm Keystone PAM4 DSP as the best-in-class solution for 800Gbps SR8 transceiver with high-performance and the lowest power consumption to meet the market demand.